Medthority· @Medthority · X·· 2 天前评分70
正文 · 原文
#ESMO26
The US bridging study ASTRIDE reported numerically longer overall survival with serplulimab plus chemotherapy versus atezolizumab plus chemotherapy in ES-SCLC.
📊 Median OS: 12.4 vs 10.2 months
Presented by @drgandara
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
29 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
来源：Medthority · x.com